Advertisement
Pharmaceutical Companies
Subscribe to Pharmaceutical Companies

The Lead

Mylan Launches Generic ORTHO EVRA Patch

April 17, 2014 8:48 am | News | Comments

Mylan has launched XULANET, the generic version of Janssen Pharmaceuticals Inc.'s ORTHO EVRA (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day).              

Astellas to Pay $7.3M Settlement

April 17, 2014 8:16 am | News | Comments

The U.S. Justice Department announced Wednesday that Astellas will pay $7.3 million to resolve...

Former NJ Drug Execs Sentenced in Stock Scheme

April 17, 2014 8:12 am | News | Comments

Two former pharmaceutical and medical technology firm executives have been sentenced for their...

GlaxoSmithKline Discloses New Bribery Inquiries

April 16, 2014 12:40 pm | by The Associated Press | News | Comments

British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations...

View Sample

FREE Email Newsletter

FDA Approves Injectable Diabetes Drug from Glaxo

April 15, 2014 5:32 pm | by The Associated Press | News | Comments

The FDA has approved a new injectable drug from GlaxoSmithKline plc for adults with Type 2 diabetes. The agency cleared the company's drug, Tanzeum, to help patients control their blood sugar levels, in combination with diet and exercise.  

DNA Alternative to Pap Smear Sparks Medical Debate

April 15, 2014 1:41 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

A high-tech screening tool for cervical cancer is facing pushback from more than a dozen U.S. patient groups, who warn that the genetic test could displace a simpler, cheaper and more established mainstay of women's health: the Pap smear.  

Prosonix Licenses Products to Mylan

April 15, 2014 8:45 am | News | Comments

PSX1001 and PSX1050, which are the first products to emerge from Prosonix's innovative and proprietary particle engineering platform, are being developed as generic versions to GlaxoSmithKline's pressurized metered dose inhalers (pMDI) Flixotide® and Flovent®, respectively.

Advertisement

FDA Approves Merck’s Allergy Treatment

April 15, 2014 8:04 am | News | Comments

Merck has announced that FDA has approved GRASTEK ® (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use [2800 Bioequivalent Allergy Units (BAU)]. GRASTEK is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis.

Johnson & Johnson Reports 2014 First-Quarter Results

April 15, 2014 7:56 am | News | Comments

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%.  Domestic sales increased 2.2%.  International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

Report: Glaxo Bribed Doctors in Poland

April 14, 2014 9:25 am | News | Comments

The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland. A "Panorama" show to air Monday evening quotes a former sales representative for the company saying doctors there were paid to prescribe its drugs.

BMS Submits NDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for HIV-1

April 14, 2014 8:18 am | News | Comments

Bristol-Myers Squibb Company announced today the submission of a new drug application (NDA) on April 4, 2014 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz®, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective.

Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts

April 14, 2014 8:02 am | News | Comments

Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the trade association’s annual meeting. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck & Co, Inc., as chairman-elect of the PhRMA Board of Directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as Board treasurer.

Advertisement

Acura Pharmaceuticals Announces Return of Product Rights

April 10, 2014 8:22 am | News | Comments

Acura Pharmaceuticals, Inc. announced today a letter of agreement with Pfizer Inc. providing for the termination of Pfizer's license to Acura's AVERSION® Technology and the return to Acura of the FDA approved Oxecta® (oxycodone HCl) product.

Biogen Idec Names SVP and Chief Strategy Officer

April 10, 2014 8:19 am | News | Comments

Biogen Idec today announced the appointment of Adam M. Koppel, M.D., Ph.D., as senior vice president and chief strategy officer, effective May 15, 2014.                 

Teva Launches Generic Fish Oil Drug

April 8, 2014 11:38 am | by Associated Press | News | Comments

Teva Pharmaceutical Industries said Tuesday it is now selling a generic version of the heart medication Lovaza, which is used to treat high triglyceride levels.                        

Promising Results For Pfizer's Cancer Drug

April 7, 2014 10:54 am | by CHRISTOPHER S. RUGABER, AP Economics Writer | News | Comments

An experimental drug has shown encouraging results in treating advanced breast cancer in an early clinical trial, pharmaceutical giant Pfizer reported Sunday.                               

Meda Turns Down Mylan

April 4, 2014 10:57 am | News | Comments

Swedish drug company Meda has rebuffed an approach from generic drug maker Mylan which was looking to combine the two businesses. Meda AB says talks between the two companies have stopped "without further actions."          

Advertisement

Arkansas to Ask Court to Reconsider Drug Fine

April 3, 2014 6:29 pm | by Andrew Demillo - Associated Press - Associated Press | News | Comments

Arkansas Attorney General Dustin McDaniel said Thursday he plans to ask the state Supreme Court to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson over the marketing of the antipsychotic drug Risperdal.

$1,000-a-Day Hepatitis C Drug Is a Blockbuster

April 3, 2014 8:56 am | Videos | Comments

Runaway demand for a life-saving hepatitis C treatment that costs $1,000 a day could send insurers' earnings per share down by double-digit percentages this year.               

Gilead Announces Results From Phase II Study of Sofosbuvir Among Hepatitis C Patients in Japan

April 3, 2014 8:22 am | News | Comments

Gilead Sciences has announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.

Hobby Lobby 401(k) Invests in Birth Control Makers

April 3, 2014 8:17 am | by SAM HANANEL, Associated Press | News | Comments

The company leading the legal challenge against birth control coverage under the new health care law offers its workers a retirement plan that includes investments in companies making contraceptive and abortion drugs.      

Novartis Top Management Quits Over Involvement in Clinical Study

April 3, 2014 8:04 am | News | Comments

Novartis Pharma K.K. said Thursday its president Yoshiyasu Ninomiya and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.     

Johnson & Johnson to be Official Healthcare Partner of the USO

April 1, 2014 3:26 pm | News | Comments

Johnson & Johnson has entered a multi-year agreement to be the Official Healthcare Partner of the USO.  The announcement was made today during a ceremony to mark the opening of the USO's Warrior and Family Center at Bethesda, located on the campus of Naval Support Activity Bethesda, home of Walter Reed National Military Medical Center.

US Court Backs Patent for Eli Lilly's Alimta

April 1, 2014 8:52 am | News | Comments

A federal court has upheld the patent that protects Eli Lilly's lung cancer treatment from generic competition until 2022.                       

EMD Serono Enters into Research Agreement with Pfizer and Broad Institute

April 1, 2014 8:04 am | News | Comments

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced they have signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients.

Effectiveness Prompts Novartis to End Drug Study

March 31, 2014 10:26 am | by The Associated Press | News | Comments

Novartis said it's cutting off late-stage research into a potential chronic heart failure treatment because the drug has proven so effective, sending shares to an all-time high when markets opened today.        

Supreme Court Takes Up Drug Company Dispute

March 31, 2014 10:11 am | News | Comments

The justices agreed Monday to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.      

FDA Approves Biogen Idec’s ALPROLIX™

March 31, 2014 8:21 am | News | Comments

Biogen Idec has announced that the FDA has approved ALPROLIX™ [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.      

Otsuka Acquires Rights to Dacogen® from Eisai

March 31, 2014 8:17 am | News | Comments

Otsuka Pharmaceutical Co., Ltd.has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen ® and to an enzyme inhibitor, E7727.                         

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading